Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 5 | 2019 | 161 | 0.600 |
Why?
|
| Hypertension | 5 | 2019 | 1535 | 0.330 |
Why?
|
| Glomerular Filtration Rate | 6 | 2019 | 274 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 232 | 0.260 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 498 | 0.260 |
Why?
|
| Heart Failure | 3 | 2009 | 1180 | 0.260 |
Why?
|
| Blood Pressure | 3 | 2019 | 1451 | 0.220 |
Why?
|
| Kidney Diseases | 3 | 2015 | 307 | 0.210 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 202 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 3 | 2009 | 365 | 0.190 |
Why?
|
| Rheumatic Diseases | 1 | 2021 | 35 | 0.180 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 53 | 0.180 |
Why?
|
| Systole | 1 | 2019 | 149 | 0.170 |
Why?
|
| Arthroplasty, Replacement | 1 | 2019 | 48 | 0.160 |
Why?
|
| Diabetes Complications | 2 | 2009 | 249 | 0.140 |
Why?
|
| alpha-Galactosidase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Fabry Disease | 1 | 2015 | 6 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 155 | 0.120 |
Why?
|
| Empyema, Pleural | 1 | 2014 | 13 | 0.120 |
Why?
|
| Isoenzymes | 1 | 2015 | 308 | 0.120 |
Why?
|
| Pneumonia | 1 | 2014 | 110 | 0.110 |
Why?
|
| Aged | 10 | 2019 | 14862 | 0.110 |
Why?
|
| Middle Aged | 11 | 2019 | 21147 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2014 | 344 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 940 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2019 | 7029 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 529 | 0.090 |
Why?
|
| Female | 12 | 2019 | 38074 | 0.080 |
Why?
|
| Stroke | 3 | 2007 | 2163 | 0.080 |
Why?
|
| Male | 11 | 2019 | 37321 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 536 | 0.070 |
Why?
|
| Humans | 14 | 2021 | 68618 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 792 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 3259 | 0.070 |
Why?
|
| Anemia | 1 | 2005 | 104 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2019 | 2358 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1603 | 0.060 |
Why?
|
| Prognosis | 1 | 2008 | 2093 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 694 | 0.050 |
Why?
|
| United States | 5 | 2017 | 7367 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2004 | 220 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1851 | 0.050 |
Why?
|
| Risk | 2 | 2019 | 563 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 4655 | 0.050 |
Why?
|
| Hospitalization | 1 | 2008 | 978 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2021 | 89 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2021 | 38 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 718 | 0.040 |
Why?
|
| Morbidity | 2 | 2009 | 130 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 243 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2017 | 31 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 115 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 4848 | 0.040 |
Why?
|
| Prevalence | 3 | 2007 | 1619 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 737 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 161 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 152 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 567 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 195 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 263 | 0.030 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 3 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 27 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 649 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 5731 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 807 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 2007 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1140 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 945 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 1330 | 0.020 |
Why?
|
| Adult | 3 | 2015 | 21403 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 242 | 0.020 |
Why?
|
| Canada | 1 | 2008 | 267 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 3705 | 0.020 |
Why?
|
| Cause of Death | 1 | 2008 | 241 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 104 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 7277 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 120 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 880 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 180 | 0.020 |
Why?
|
| Geography | 1 | 2006 | 80 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1056 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1738 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.020 |
Why?
|
| Family | 1 | 2007 | 293 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2004 | 39 | 0.010 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2004 | 50 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 867 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2007 | 2279 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2673 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 2550 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 20881 | 0.000 |
Why?
|